Sun Pharma Q1 preview: Subdued growth on weak Taro numbers, muted US sales
Analysts expect a ramp-up in select specialty products to offset some impact of restrictions at Halol and Mohali plants for Sun Pharma.
Stay updated with breaking news from Result Poll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Analysts expect a ramp-up in select specialty products to offset some impact of restrictions at Halol and Mohali plants for Sun Pharma.
Based on the mean consensus of four brokerage firms, the company is expected to report a 7.18 percent YoY increase in its revenue at Rs 4,280 crore in Q1FY24.
Net profit is seen increasing merely three percent on year to Rs 442.4 crore in the June quarter.
L&T recently announced its first-ever share buyback. Details of the buyback, along with the special dividend, will be disclosed by the company today, while announcing the results. Market participants are keenly awaiting these details.
Continued boost from sales of the blockbuster drug Revlimid along with launches of a few inhalation drug is expected to fuel a jump in US sales for Dr Reddy's.